

Registration

<https://pretix.eu/goegitdk/ppriconference2024>

Contact

ppriconference@goeg.at

<https://ppri.goeg.at/ppriconference2024>



Fees

Standard fee

- Registration until 31 January 2024: EUR 840.-
- After 31 January 2024: EUR 1080.-

Reduced fee

(for governmental / public bodies / authorities / universities)

- Registration until 31 January 2024: EUR 540.-
- After 31 January 2024: EUR 700.-

All registration fees include

- Participation in all activities in the conference programme (incl. conference workshops)
- Refreshments and lunch on both days
- Reception at the venue on 25 April 2024

Gesundheit Österreich
GmbH



WHO Collaborating Centre
for Pharmaceutical Pricing
and Reimbursement Policies

5th PPRI Conference

Ensuring access to
affordable medicines
through innovative policies

Thursday, 25 April 2024 - Friday, 26 April 2024

Vienna, Austria

Palais Niederösterreich, Herrengasse 33



Call for Abstracts

Specific sessions at the conference are dedicated to researchers and policy-makers to present and discuss pharmaceutical policies.

Submit your abstract(s) either for a 10-min talk or a poster presentation by
15 January 2024, 23:59 CET.

ppri.goeg.at/ppriconference2024_abstracts

Organiser

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department at the Austrian National Public Health Institute (Gesundheit Österreich GmbH)

About

Equitable access to quality-assured, safe and affordable medicines, vaccines and medical devices is fundamental to a functioning health system. Over the last few decades, innovations in life sciences have saved millions of lives yet millions more worldwide still suffer from a lack of access to medicines that they would need for acute and/or chronic diseases. A variety of pharmaceutical policies in pricing, procurement and reimbursement is used in different healthcare systems to ensure equitable access to medicines for all patients at affordable costs. Multifaceted challenges require comprehensive approaches but are current policies designed appropriately to achieve the desired outcomes? Are health systems prepared to address future developments while current challenges in affordable and equitable access are yet to be met? Thus, innovative policies are needed.

Key topics

Strand 1: Local challenges, global learnings?

What can we learn from experience, including good-practice examples, in the field of pharmaceutical pricing, procurement and reimbursement policies in other countries?

Strand 2: Strengthening the evidence base.

How can we promote equitable access to affordable and cost-effective medicines by generating and sharing evidence? The role of managed entry agreements (MEAs), increased transparency, real-world data and health technology assessments.

Strand 3: Futureproofing pharma policies.

How can innovation in policy-making improve equitable access to affordable and cost-effective medicines? Fair pricing concepts, crisis preparedness, considering environmental aspects and increased patient involvement as well as coordination and collaboration are all drivers for the future.



Programme

Day 1: Thursday, 25 April 2024 (09:00-17:30)

- Key note presentations & stakeholder roundtable
- Three parallel sessions to the three strands
- Poster walk and moderated poster session

Day 2: Friday, 26 April 2024 (08:00 - 16:00)

- Meet-the-Editors session
- Key note presentations
- Country poster presentations:
 - European Union/European Economic Area
 - Further countries of the WHO European Region (incl. Central Asia)
 - Non-European countries
- Three parallel sessions to the three strands
- Conference workshops
- Conclusions, awards and closure



Who should attend

- Public authorities responsible for the pricing and reimbursement of medicines (policy-makers, administration)
- Payers in the health care system (e.g. public and private social health insurance institutions, ministries, medicines agencies)
- Procurement bodies
- Researchers, academics and students
- Patients and consumers and their advocates
- Health professionals (e.g. pharmacists, physicians) and their professional associations
- Economic actors (e.g. pharmaceutical companies and their professional associations, distributors)
- Editors, journalists



Objectives

- Present research findings and cutting-edge academic analyses as well as showcase best practice examples of pharmaceutical pricing and reimbursement policies;
- Discuss current challenges and develop strategies to tackle them;
- Support policy-makers by offering tools so that they can be well prepared and equipped to address the future challenges, and
- Allow for networking.